A newly launched clinical study combining e-OPRA™, targeted muscle reinnervation and advanced signal decoding through implanted sensors is now getting underway at Shirley Ryan AbilityLab, the leading rehabilitation hospital in the US. The program is supported by a five-year clinical research grant of USD 8.7 million to Shirley Ryan AbilityLab from the National Institutes of Health (NIH). Through these research and development efforts, Integrum has established a unique position at the intersection of neural interfaces, osseointegration, and intelligent bionics.
News Published
Shirley Ryan AbilityLab runs first e-OPRA study in the US
Shirley Ryan AbilityLab launches the first US patient study to combine Integrum's e-OPRA™ with advanced signal decoding.
More news
Watch Integrum's Q1 presentation
On Thursday September 3rd 2026, CEO Martin Hillsten and CFO Louise Wåhlin presented the company’s results...
Publicerad: 3 September, 2026
Integrum's Q1 report
Read Integrum’s interim report for the first quarter of the company’s financial year.
Publicerad: 3 September, 2026
Comment
From transformation to acceleration
The first quarter of our new financial year clearly shows that Integrum continues to develop in the right...
Publicerad: 3 September, 2026
Annual General Meeting 2026
The shareholders of Integrum AB, 556407-3145 (the “Company”), are hereby invited to the Annual General...
Publicerad: 31 August, 2026
Notice of Annual General Meeting
The shareholders of Integrum are hereby invited to the Annual General Meeting on 29 September 2026 at...
Publicerad: 27 August, 2026